Your browser is no longer supported. Please, upgrade your browser.
HEB Hemispherx Biopharma, Inc. daily Stock Chart
Hemispherx Biopharma, Inc.
Index- P/E- EPS (ttm)-9.62 Insider Own6.60% Shs Outstand2.33M Perf Week2.12%
Market Cap4.50M Forward P/E- EPS next Y-4.46 Insider Trans111.81% Shs Float2.02M Perf Month-30.07%
Income-10.50M PEG- EPS next Q-1.72 Inst Own3.70% Short Float6.60% Perf Quarter-66.18%
Sales0.30M P/S14.99 EPS this Y22.90% Inst Trans- Short Ratio0.76 Perf Half Y-78.86%
Book/sh3.45 P/B0.56 EPS next Y37.50% ROA- Target Price17.20 Perf Year-82.83%
Cash/sh1.24 P/C1.55 EPS next 5Y25.00% ROE- 52W Range1.69 - 14.81 Perf YTD-75.77%
Dividend- P/FCF- EPS past 5Y28.20% ROI-99.30% 52W High-86.97% Beta0.88
Dividend %- Quick Ratio2.10 Sales past 5Y19.60% Gross Margin- 52W Low14.20% ATR0.27
Employees31 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)23.73 Volatility9.38% 11.68%
OptionableNo Debt/Eq0.72 EPS Q/Q- Profit Margin- Rel Volume0.33 Prev Close1.92
ShortableNo LT Debt/Eq0.69 EarningsAug 21 AMC Payout- Avg Volume175.06K Price1.93
Recom2.00 SMA20-9.18% SMA50-41.29% SMA200-71.91% Volume57,868 Change0.40%
Apr-02-15Initiated Midtown Partners Strong Buy $1.45
Jan-21-14Initiated Chardan Capital Markets Buy $3
Dec-10-07Downgrade Boenning & Scattergood Market Outperform → Market Perform
Aug-23-19 06:50AM  Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligens® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS GlobeNewswire
Aug-15-19 06:45AM  Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials GlobeNewswire
Aug-08-19 08:49AM  Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified? Simply Wall St. +7.25%
06:50AM  Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen® GlobeNewswire
Aug-02-19 06:45AM  Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing GlobeNewswire
Jul-09-19 01:58PM  5 Immunotherapy Stocks to Keep a Close Eye On
Jul-02-19 08:30AM  Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on ACCESSWIRE -8.81%
Jun-28-19 07:00AM  Hemispherx Biopharma CFO Adam Pascale Announces Retirement GlobeNewswire
Jun-25-19 03:15PM  Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ... +8.54%
Jun-24-19 11:21AM  Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares? Simply Wall St.
Jun-21-19 01:15PM  Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...
Jun-17-19 08:30AM  Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program GlobeNewswire -5.51%
Jun-13-19 09:27AM  Company News For Jun 13, 2019 Zacks -20.86%
07:16AM  How Does Investing In Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Impact The Volatility Of Your Portfolio? Simply Wall St.
Jun-12-19 03:31PM  Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin GlobeNewswire +21.80%
May-31-19 10:16AM  Hemispherx Biopharma Stockholders Approve Reverse Stock Split GlobeNewswire -11.11%
May-16-19 08:30AM  Hemispherx Reports 2019 First Quarter Financial Results GlobeNewswire
May-13-19 12:22PM  Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma GlobeNewswire
08:30AM  Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center GlobeNewswire
May-08-19 08:30AM  Hemispherx Biopharma's CEO to Attend BioFlorida Inc.s 2019 Celebration of Biotechnology GlobeNewswire -5.57%
May-06-19 08:30AM  Hemispherx Links Stanfords ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization GlobeNewswire
May-01-19 08:00AM  Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress ACCESSWIRE
Apr-30-19 08:30AM  Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program GlobeNewswire +20.59%
Apr-25-19 08:30AM  Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019 GlobeNewswire
Apr-23-19 08:30AM  MicroCap Review Magazine Spring 2019 Issue Now Available ACCESSWIRE
Apr-22-19 08:30AM  Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer GlobeNewswire
Apr-13-19 09:16AM  Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out Simply Wall St.
Apr-02-19 08:30AM  Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx Ampligen and Pembrolizumab GlobeNewswire
Apr-01-19 05:30PM  Hemispherx Reports 2018 Year-end Financial Results GlobeNewswire
Mar-13-19 09:06AM  Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs GlobeNewswire +10.89%
Mar-06-19 08:25AM  Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering GlobeNewswire
Feb-28-19 10:30AM  Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020 GlobeNewswire +6.26%
08:30AM  Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019 GlobeNewswire
Feb-27-19 08:30AM  Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering GlobeNewswire -15.72%
Feb-15-19 06:00AM  Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period GlobeNewswire
Feb-12-19 02:17PM  Hemispherx Biopharma Reminds Investors of Todays Deadline to be a Stockholder of Record GlobeNewswire
Feb-11-19 08:30AM  Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Mercks Keytruda in the Treatment of Recurrent Ovarian Cancer GlobeNewswire
Feb-06-19 05:34PM  Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering GlobeNewswire +11.01%
Jan-31-19 08:30AM  Hemispherx Biopharma Shares CEOs Presentation at the NobleConXV Conference GlobeNewswire
Jan-28-19 07:40AM  Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-24-19 11:59AM  REPEAT - Hemispherx Biopharmas CEO to Present at the 15th Annual NobleConXV Conference GlobeNewswire
Jan-23-19 12:00AM  Hemispherx Biopharmas CEO to Present at the 15th Annual NobleConXV Conference GlobeNewswire
Jan-08-19 12:50PM  Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center GlobeNewswire +22.06%
Jan-02-19 08:30AM  Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome GlobeNewswire
Dec-26-18 08:30AM  Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application No Recent Stories Misinformation GlobeNewswire
Dec-19-18 08:30AM  Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program GlobeNewswire +19.12%
Dec-17-18 08:30AM  Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States GlobeNewswire +5.65%
Dec-12-18 08:30AM  Hemispherx Biopharma Issues Letter to Stockholders GlobeNewswire +5.50%
Dec-11-18 07:35AM  Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire -8.76%
Nov-15-18 09:04AM  Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results GlobeNewswire -6.85%
Oct-29-18 06:39PM  Hemispherxs Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed GlobeNewswire
Oct-24-18 08:30AM  Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire
Oct-22-18 08:30AM  Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders GlobeNewswire
Oct-18-18 09:20AM  Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-10-18 08:30AM  Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma GlobeNewswire
Sep-18-18 08:30AM  Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe GlobeNewswire
Aug-28-18 08:30AM  Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order GlobeNewswire
Aug-24-18 08:30AM  Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-15-18 08:38AM  Hemispherx Reports Six Months Ended June 30, 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-13-18 08:30AM  Hemispherx Updates Stockholders, Highlighting Ampligens Role in Enhancing Immunotherapeutic Therapies GlobeNewswire
Jul-30-18 07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-09-18 08:30AM  Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine GlobeNewswire
Jul-03-18 08:30AM  Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies GlobeNewswire
Jun-29-18 07:10AM  Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-27-18 08:30AM  Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina GlobeNewswire
Jun-22-18 08:15AM  Report: Developing Opportunities within Sonic Automotive, PJT Partners, YRC Worldwide, SecureWorks, Manhattan Associates, and Hemispherx BioPharma Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-15-18 10:19AM  Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot GlobeNewswire
Jun-05-18 11:21AM  Hemispherx Announces New Data Showing Ampligens Positive Role in Reprograming Tumor Microenvironment GlobeNewswire +6.30%
May-31-18 08:30AM  Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors GlobeNewswire +5.46%
May-25-18 04:33PM  How Has Hemispherx Biopharma Incs (NYSEMKT:HEB) Performed Against The Industry? Simply Wall St.
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE
May-16-18 02:19PM  CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
08:30AM  Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-14-18 08:30AM  Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum GlobeNewswire
May-10-18 08:30AM  Hemispherx to Present at the 8th Annual LD Micro Invitational GlobeNewswire
May-03-18 08:30AM  Research Report Identifies Systemax, C&J Energy Services, Seritage Growth Properties, Hemispherx BioPharma, YRC Worldwide, and Westlake Chemical Partners LP with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-02-18 08:30AM  Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials GlobeNewswire
Apr-20-18 09:28AM  Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market GlobeNewswire -6.58%
Apr-19-18 07:30AM  Wired News ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World ACCESSWIRE
Apr-17-18 08:30AM  Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs GlobeNewswire
Apr-04-18 08:30AM  Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients GlobeNewswire -7.20%
Apr-02-18 08:30AM  Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017 GlobeNewswire +18.99%
Mar-19-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Government Properties Income Trust, Grand Canyon Education, The Chefs' Warehouse, Hemispherx BioPharma, Revlon, and Blueprint Medicines Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-14-18 08:30AM  Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer GlobeNewswire -5.89%
Mar-05-18 08:30AM  Hemispherx to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-27-18 08:30AM  Hemispherx to Present at the Inaugural LD Micro Virtual Conference GlobeNewswire -11.37%
Feb-26-18 08:30AM  Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program GlobeNewswire
Jan-31-18 08:30AM  Hemispherxs Ampligen Highlighted in Review of Role of TLR3 Agonist Support for Universal Flu Immunization Development Programs GlobeNewswire
Jan-29-18 08:30AM  Hemispherx to Present at the BIO CEO & Investor Conference GlobeNewswire -5.88%
Jan-26-18 08:30AM  Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection GlobeNewswire
Jan-25-18 08:30AM  Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors GlobeNewswire -5.05%
Jan-24-18 01:30PM  HEB: Recent AdvancementsWhat Do They Imply? Zacks Small Cap Research +7.27%
Jan-23-18 08:30AM  Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S. GlobeNewswire +5.56%
Jan-19-18 12:53PM  Here's Why the 2 Latest Hemispherx BioPharma Announcements Are Important -7.28%
Jan-17-18 08:30AM  Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility GlobeNewswire -12.92%
07:35AM  Recent Analysis Shows XOMA, Washington Real Estate Investment Trust, TransMontaigne Partners, Triumph, Hemispherx BioPharma, and Virtus Investment Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-11-18 08:30AM  Hemispherx Enhances Manufacturing Efficiency of Ampligen GlobeNewswire
Jan-09-18 08:30AM  Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference, Jan 24 GlobeNewswire +9.95%
08:20AM  Todays Research Reports on Trending Tickers: Galectin Therapeutics and Hemispherx BioPharma ACCESSWIRE
Jan-03-18 08:30AM  Hemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on ACCESSWIRE
Hemispherx Biopharma, Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was founded in 1966 and is headquartered in Ocala, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Jun 27Buy4.372,63211,50263,041Jun 27 03:32 PM
RODINO III PETER W.Dir Govt Relations/SectryJun 21Buy4.038,69535,04112,590Jun 25 11:04 AM
STRAYER DAVID RChief Science/Medical OfficerJun 21Buy4.032,4819,9985,420Jun 25 11:40 AM
APPELROUTH STEWARTDirectorJun 21Buy4.039,67738,99826,708Jun 25 10:19 AM
SPRINGATE WAYNE SSr. VP of OperationsJun 21Buy4.035,21121,0008,672Jun 24 05:01 PM
MITCHELL WILLIAM MDirectorJun 21Buy4.039,67738,99820,838Jun 24 04:14 PM
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Jun 21Buy4.0329,404118,4981,393,611Jun 21 11:11 AM
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Mar 19Buy0.1813,4002,352811,707Mar 19 04:01 PM
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Nov 30Buy0.1920,0003,845798,307Dec 03 11:32 AM
APPELROUTH STEWARTDirectorNov 05Buy0.2225,2385,552266,988Nov 06 11:24 AM
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Oct 26Buy0.203,500711775,807Oct 29 09:14 AM
EQUELS THOMAS K.Exec. Vice Chairman/CEO/Pres.Oct 25Buy0.20100,00020,000772,307Oct 25 09:22 AM